YF438 is an HDAC inhibitor that demonstrates potent anti-cancer activity both in vitro and in vivo. It inhibits the growth and metastasis of triple-negative breast cancer (TNBC) cells by blocking the interaction between HDAC and MDM2, inducing the dissociation of MDM2 from MDMX, and promoting the degradation of MDM2.